Is lenalidomide a new standard treatment for myelodysplastic syndrome?

被引：0
|
作者：
Kuendgen, Andrea [1 ]
机构：
[1] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, D-40225 Dusseldorf, Germany
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2007年 / 4卷 / 07期
关键词：
anemia; lenalidomide; myelodysplastic syndrome; red-blood-cell transfusion;
D O I：
10.1038/ncponc0823
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：396 / 397
页数：2
相关论文
共 50 条
  • [31] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
    Butrym, Aleksandra
    Lech-Maranda, Ewa
    Patkowska, Elzbieta
    Kumiega, Beata
    Bieniaszewska, Maria
    Mital, Andrzej
    Madry, Krzysztof
    Torosian, Tigran
    Wichary, Ryszard
    Rybka, Justyna
    Warzocha, Krzysztof
    Mazur, Grzegorz
    [J]. BMC CANCER, 2015, 15
  • [32] Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
    Serin, Istemi
    Eren, Rafet
    Dogu, Mehmet Hilmi
    [J]. JOURNAL OF HEMATOLOGY, 2020, 9 (1-2) : 33 - 36
  • [33] TREATMENT OF THE MYELODYSPLASTIC SYNDROME
    AUL, C
    HEYLL, A
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1990, 115 (48) : 1842 - 1850
  • [34] Efficacy of lenalidomide for treatment of anemia in secondary myelodysplastic syndrome (MDS) with chromosome 5q deletion
    Mintzer, David Michael
    Billet, Shira N.
    [J]. BLOOD, 2007, 110 (11) : 226B - 226B
  • [35] Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience
    Le Bras, Fabien
    Sebert, Marie
    Kelaidi, Charikleia
    Lamy, Thierry
    Dreyfus, Francois
    Delaunay, Jacques
    Banos, Anne
    Blanc, Michel
    Vey, Norbert
    Schmidt, Aline
    Visanica, Sorin
    Eclache, Virginie
    Turlure, Pascal
    Beyne-Rauzy, Odile
    Guerci, Agnes
    Delmer, Alain
    de Botton, Stephane
    Rea, Delphine
    Fenaux, Pierre
    Ades, Lionel
    [J]. LEUKEMIA RESEARCH, 2011, 35 (11) : 1444 - 1448
  • [36] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
    Aleksandra Butrym
    Ewa Lech-Maranda
    Elżbieta Patkowska
    Beata Kumiega
    Maria Bieniaszewska
    Andrzej Mital
    Krzysztof Madry
    Tigran Torosian
    Ryszard Wichary
    Justyna Rybka
    Krzysztof Warzocha
    Grzegorz Mazur
    [J]. BMC Cancer, 15
  • [37] Lenalidomide for Treatment of Myelodysplastic Syndromes: Current Status and Future Directions
    Komrokji, Rami S.
    List, Alan F.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 24 (02) : 377 - +
  • [38] Pulmonary Zygomycosis in a Non-neutropenic Patient With Myelodysplastic Syndrome on Lenalidomide
    Theisen-Toupal, Jesse
    Rosenthal, Elana S.
    Kelly, Emer
    Zwicker, Jeffrey I.
    Akuthota, Praveen
    Roberts, David H.
    [J]. RESPIRATORY CARE, 2012, 57 (07) : 1175 - 1177
  • [39] Lenalidomide linked to low reporting rate of VTE in patients with myelodysplastic syndrome
    [J]. Reactions Weekly, 2009, 1244 (1) : 3 - 3
  • [40] New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide
    Loiseau, Clemenee
    Ali, Ashfaq
    Itzykson, Raphael
    [J]. EXPERIMENTAL HEMATOLOGY, 2015, 43 (08) : 661 - 672
12345